0001415889-20-000755.txt : 20200316
0001415889-20-000755.hdr.sgml : 20200316
20200316161015
ACCESSION NUMBER: 0001415889-20-000755
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200315
FILED AS OF DATE: 20200316
DATE AS OF CHANGE: 20200316
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WEAVER GREGORY L
CENTRAL INDEX KEY: 0001251779
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31326
FILM NUMBER: 20717228
MAIL ADDRESS:
STREET 1: 185 BERRY STREET
STREET 2: SUITE 6504
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94107
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Eloxx Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001035354
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 841368850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 950 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (858) 909-0749
MAIL ADDRESS:
STREET 1: 950 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: Sevion Therapeutics, Inc.
DATE OF NAME CHANGE: 20140930
FORMER COMPANY:
FORMER CONFORMED NAME: SENESCO TECHNOLOGIES INC
DATE OF NAME CHANGE: 19991006
FORMER COMPANY:
FORMER CONFORMED NAME: NAVA LEISURE USA INC
DATE OF NAME CHANGE: 19970310
4
1
form4-03162020_040301.xml
X0306
4
2020-03-15
1
0001035354
Eloxx Pharmaceuticals, Inc.
ELOX
0001251779
WEAVER GREGORY L
C/O ELOXX PHARMACEUTICALS, INC.
950 WINTER STREET
WALTHAM
MA
02451
false
false
false
true
FORMER CHIEF FINANCIAL OFFICER
Common Stock
2020-03-15
4
M
0
3750
0
A
11517
D
Common Stock
2020-03-15
4
F
0
1086
2.85
D
10431
D
Restricted Stock Units
2020-03-15
4
M
0
3750
0
D
Common Stock
3750
0
D
The restricted stock units issued to the reporting person on January 30, 2019 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock.
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan.
As a result of reporting person's separation from the Issuer, 25% of all unvested equity accelerated in accordance with the reporting person's employment agreement and the remaining unvested equity was forfeited.
/s/ Neil S. Belloff, Attorney-in-Fact
2020-03-16